Liminatus Pharma, Inc. — financial figures as filed
CIK 1971387 · 3 fiscal years on record
Every figure below is taken from a filed report through an explicit tag map and carries the tag and accession number it came from. A metric the company did not disclose is shown as —, never as zero.
Aggregates
computed from the figures belowMetrics filled
9 / 12
canonical metrics mapped from the filings
Mapping completeness
75.0%
3 not disclosed
Fiscal years on record
3
Quarters on record
7
Revenue change, latest year
—
against the preceding fiscal year
Revenue growth run
0 yr
consecutive years higher than the previous
Years with income above zero
0
2 years below zero on record
Revenue rank in peer group
—
by latest annual revenue
Disclosure lag
90 d
period end to filing date
Latest period end
2025-12-31
filed 2026-03-31
Periods that do not reconcile
0
four quarters against the reported year
Explainable annual analytics
latest annual period where both published inputs existRatios are arithmetic over reported SEC facts, not ratings, forecasts or investment advice.
| Metric | Value | Fiscal year | Inputs | Source tags |
|---|---|---|---|---|
| Return on assets | -1,990.4% | FY2025 | Net income: -$10.2MTotal assets: $512.8K | NetIncomeLoss / Assets |
| Return on equity | 104.0% | FY2025 | Net income: -$10.2MShareholders equity: -$9.8M | NetIncomeLoss / StockholdersEquity |
| Liabilities / assets | 2,014.0% | FY2025 | Total liabilities: $10.3MTotal assets: $512.8K | Liabilities / Assets |
Not computed: Gross margin — both metrics are not available for a common annual period; Operating margin — both metrics are not available for a common annual period; Net margin — both metrics are not available for a common annual period; Operating cash-flow margin — both metrics are not available for a common annual period; Cash / assets — both metrics are not available for a common annual period.
Mapping completeness
9 of 129 of 12 canonical metrics were filled from this company's filings through the explicit tag map. Tags outside that map are recorded and counted, and are never used as a value.
Not on record for this company: Revenue, Gross profit, Cash and equivalents. This means the figure was not disclosed in a form we accept, not that it is zero.
Annual figures
3 fiscal years shown| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating income | -$3M | -$3.3M | — |
| Net income | -$10.2M | -$3.5M | — |
| Operating cash flow | -$10M | -$1.5M | — |
| Total assets | $512.8K | $5.4M | — |
| Total liabilities | $10.3M | $24.7M | — |
| Shareholders equity | -$9.8M | -$19.3M | -$15.8M |
| Shares outstanding | 27,064,633 | 17,500,000 | — |
| EPS, basic | -$0.43 | -$0.20 | — |
| EPS, diluted | -$0.43 | -$0.20 | — |
Quarterly figures
7 fiscal quarters shown| Metric | 2026 Q1 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q3 | 2024 Q2 | 2024 Q1 |
|---|---|---|---|---|---|---|---|
| Operating income | -$1.1M | -$701.2K | -$1.1M | -$255 | -$543.1K | -$909.2K | -$247 |
| Net income | -$1.1M | -$1.8M | $113.3K | -$255 | -$601.4K | -$961.2K | -$1.8M |
| Operating cash flow | -$2M | — | — | $0 | — | — | $0 |
| Total assets | $2.8M | $1.3M | $1.9M | — | — | — | — |
| Total liabilities | $2.9M | $3M | $10.7M | $1.1K | — | — | — |
| Shareholders equity | -$132.6K | -$1.6M | -$8.8M | -$1.1K | -$19.1M | -$18.5M | -$17.5M |
| Shares outstanding | 44,877,633 | 27,064,633 | 26,014,633 | — | — | — | — |
| EPS, basic | -$0.03 | -$0.07 | $0.00 | -$2.55 | -$0.03 | -$0.05 | -$2.47 |
| EPS, diluted | -$0.03 | -$0.07 | $0.00 | -$2.55 | -$0.03 | -$0.05 | -$2.47 |
Latest figure against the peer median
all 722 companies with figures on recordAn industry classification is not on record for this company, so the comparison group is every company whose figures we hold, across all sectors. The median is stated with the group it was computed over; it is a fact about that group and nothing more.
| Metric | Latest annual figure | Peer median | Difference | Companies in group | Source tag |
|---|---|---|---|---|---|
| Operating income · FY2025 | -$3M | -$3.8M | +21.8% | 591 | OperatingIncomeLoss |
| Net income · FY2025 | -$10.2M | $2.4M | −517.1% | 716 | NetIncomeLoss |
| Operating cash flow · FY2025 | -$10M | $20.1M | −149.5% | 715 | NetCashProvidedByUsedInOperatingActivities |
| Total assets · FY2025 | $512.8K | $1.1B | −100.0% | 720 | Assets |
| Total liabilities · FY2025 | $10.3M | $458.2M | −97.7% | 664 | Liabilities |
| Shareholders equity · FY2025 | -$9.8M | $301M | −103.3% | 716 | StockholdersEquity |
| Shares outstanding · FY2025 | 27,064,633 | 49,628,137 | −45.5% | 606 | CommonStockSharesOutstanding |
| EPS, basic · FY2025 | -$0.43 | $0.05 | −960.0% | 678 | EarningsPerShareBasic |
| EPS, diluted · FY2025 | -$0.43 | $0.03 | −1,820.0% | 678 | EarningsPerShareDiluted |
Where the numbers come from
every figure traces to a filing| Metric | Fiscal period | Period end | Filed | Form | Accession | XBRL tag |
|---|---|---|---|---|---|---|
| Operating income | FY2025 | 2025-12-31 | 2026-03-31 | 10-K | 0001104659-26-037933 | OperatingIncomeLoss |
| Net income | FY2025 | 2025-12-31 | 2026-03-31 | 10-K | 0001104659-26-037933 | NetIncomeLoss |
| Operating cash flow | FY2025 | 2025-12-31 | 2026-03-31 | 10-K | 0001104659-26-037933 | NetCashProvidedByUsedInOperatingActivities |
| Total assets | FY2025 | 2025-12-31 | 2026-03-31 | 10-K | 0001104659-26-037933 | Assets |
| Total liabilities | FY2025 | 2025-12-31 | 2026-03-31 | 10-K | 0001104659-26-037933 | Liabilities |
| Shareholders equity | FY2025 | 2025-12-31 | 2026-03-31 | 10-K | 0001104659-26-037933 | StockholdersEquity |
| Shares outstanding | FY2025 | 2025-12-31 | 2026-03-31 | 10-K | 0001104659-26-037933 | CommonStockSharesOutstanding |
| EPS, basic | FY2025 | 2025-12-31 | 2026-03-31 | 10-K | 0001104659-26-037933 | EarningsPerShareBasic |
| EPS, diluted | FY2025 | 2025-12-31 | 2026-03-31 | 10-K | 0001104659-26-037933 | EarningsPerShareDiluted |
Source: U.S. Securities and Exchange Commission, EDGAR company facts · as of 2026-03-31